Accelerated Synthesis of Agrochemicals and Pharmaceuticals (ASAP): Bridging the Gap Between Research and Application

食品和医疗保健是我们当前生活质量的基础。随着英国人口老龄化，全球人口将在2050年达到90亿，气候变化的最坏影响开始显现，这些资源的压力只会增加。现在比以往任何时候都更需要新的药物和农用化学品，以应对社会面临的日益增长和不断变化的威胁。开发新药物和农用化学品的一个主要挑战是正在研究的候选分子的高损耗率，这增加了将新产品推向市场的财务成本、环境影响和时间。因此，能够快速、低成本、低资源地制备理想候选分子的方法是非常有价值的。该计划将提供一套合成方法，以简化下一代农用化学品和药品的发现和开发。基于我们最近的发现，我们将开发新的方法来制造有价值的分子结构，同时最大限度地减少所需的化学操作次数，避免使用有毒或珍贵的元素。通过与作物保护（先正达）和人类医疗保健（阿斯利康，辉瑞和Carbometrics）领域的领先创新者密切合作，我们将确保我们的方法将直接和立即受益。我们还将寻求使我们开发的试剂商业化，从而进一步使我们的方法能够快速和无障碍地采用。

Food and healthcare are the foundations on which our current quality of life is built. The pressure on these resources will only increase as the UK population ages, the global population reaches 9 billion in 2050 and the worst effects of climate change begin to manifest. Now more than ever, new medicines and agrochemicals will be vital in combating the growing and evolving threats that face society. A major challenge to the development of new medicines and agrochemicals is the high attrition rate of the candidate molecules being investigated, which drives up the financial cost, environmental impact and time associated with bringing a new product to market. Methods that allow rapid cost- and resource efficient preparation of desirable candidate molecules are therefore extremely valuable. This programme will deliver a suite of synthesis methods to streamline the discovery and development of the next generation of agrochemicals and pharmaceuticals. Building on our recent discovery, we will develop new ways of making valuable molecular architectures while minimising the number of chemical operations required and avoiding the use of toxic or precious elements. By working in close collaboration with leading innovators in crop protection (Syngenta) and human healthcare (AstraZeneca, Pfizer and Carbometrics), we will ensure that our methods will be of direct and immediate benefit. We will also seek to make the reagents we develop commercially available, thus further enabling the rapid and barrierless uptake of our methods.